Key Takeaways: 5-Year Data on TAVR for Failing Surgical Valves
Key Takeaways: 5-Year Data on TAVR for Failing Surgical Valves
The data were presented as a late-breaker at the Cardiovascular Research Technologies (CRT) 2025 conference this month.
• Positive 5-Year Outcomes: The PARTNER 3 Aortic Valve-in-Valve Registry showed 11% mortality at five years, supporting TAVR as a viable option for failing bioprosthetic valves.
• Study Population: 100 low- and intermediate-risk patients underwent transfemoral TAVR using the Sapien 3 valve.
• Clinical Implications: Results may help expand TAVR eligibility beyond high-risk patients.
• Lifetime Management Considerations: Younger patients receiving bioprosthetic valves may benefit from an SAVR-first approach, preserving future TAVR options.
• Hemodynamics & Optimization: Pressure gradients remained at 17-19 mmHg at five years. Surgical root enlargement and optimized valve sizing could improve long-term TAVR-in-TAVR feasibility.
